title: Inadequate seroprotection against hepatitis B virus and one detected case of hepatitis C virus infection among patients with inflammatory bowel disease.
abstract: OBJECTIVE
  The prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections among patients with inflammatory bowel disease (IBD) from central and eastern European countries is unknown. Postvaccination HBV immunity in an immunocompromised host may wane. The aims of the study were as follows: to assess the immune status for HBV and HCV among IBD patients, the level of HBV seroprotection, and to compare the immune status of patients who received mandatory versus recommended HBV vaccination.
  
  
  METHODS
  Serological markers of HBV and HCV (anti-HBs, anti-HBc, HBsAg, and anti-HCV) were determined in 147 consecutive IBD patients. An anti-HBs of 10 IU/l or more was considered as immunity to HBV infection.
  
  
  RESULTS
  HBV infection was detected in 21 patients, whereas 11 of them recalled previous HBV vaccination. Sixty-eight noninfected patients had a level of anti-HBs 10 IU/l or more and only 29% reached the cut-off level of 100 IU/l. Among patients vaccinated obligatorily, two patients had previous HBV infection and 15% did not have an adequate seroprotection against HBV. Patients who received a mandatory HBV vaccine more frequently had a protective anti-HBs level than those vaccinated voluntarily (P<0.001). One positive anti-HCV result was found.
  
  
  CONCLUSIONS
  A mandatory HBV vaccination significantly increased the number of patients effectively protected against HBV; however, a remarkable number of vaccinated IBD patients had inadequate HBV seroprotection. All IBD patients should be screened for HBV and HCV infections and monitored for anti-HBs titers.
authors.affiliation: Departments of aGastroenterology and Hepatology bPaediatrics and Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Waszczuk
authors.forename: Karolina M
authors.initials: KM
authors.lastname: Waszczuk
authors.forename: Agata
authors.initials: A
authors.lastname: Mulak
authors.forename: Leszek
authors.initials: L
authors.lastname: Paradowski
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D006510:Hepatitis B Antibodies / Q000276:immunology; D006512:Hepatitis B Core Antigens / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000627:therapeutic use; D019694:Hepatitis B, Chronic / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D018937:Hepatitis C Antibodies / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000453:epidemiology* / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D015212:Inflammatory Bowel Diseases / Q000453:epidemiology* / Q000276:immunology; D008297:Male; D011044:Poland / Q000453:epidemiology; D015995:Prevalence; D055815:Young Adult
chemical_list: D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D018937:Hepatitis C Antibodies